

Maksymilian Fraszka is a results-driven finance professional with a strong foundation in the MedTech and biotech sectors. With a proven track record of driving operational efficiency and cost savings through effective forecasting and financial analysis, Maks brings both strategic insight and technical skill to corporate finance teams. Currently serving as a Financial Analyst at ImmunityBio (NASDAQ: IBRX), he supports key G&A functions through budgeting, variance analysis, and monthly reporting.

Maks holds a Bachelor of Science in Finance from the University of Illinois at Chicago, graduating Magna Cum Laude with College Honors.